AbCellera Biologics Inc (NASDAQ: ABCL) has seen a decline in its stock price by -1.70 in relation to its previous close of 4.11. However, the company has experienced a 6.88% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-07 that AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.14 per share a year ago.
Is It Worth Investing in AbCellera Biologics Inc (NASDAQ: ABCL) Right Now?
The 36-month beta value for ABCL is also noteworthy at 0.44. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABCL is 205.97M, and at present, short sellers hold a 11.21% of that float. The average trading volume of ABCL on May 08, 2024 was 1.39M shares.
ABCL’s Market Performance
ABCL’s stock has seen a 6.88% increase for the week, with a -10.02% drop in the past month and a -22.01% fall in the past quarter. The volatility ratio for the week is 6.41%, and the volatility levels for the past 30 days are at 5.68% for AbCellera Biologics Inc The simple moving average for the past 20 days is 0.37% for ABCL’s stock, with a -19.28% simple moving average for the past 200 days.
Analysts’ Opinion of ABCL
Many brokerage firms have already submitted their reports for ABCL stocks, with The Benchmark Company repeating the rating for ABCL by listing it as a “Buy.” The predicted price for ABCL in the upcoming period, according to The Benchmark Company is $9 based on the research report published on February 22, 2024 of the current year 2024.
KeyBanc Capital Markets, on the other hand, stated in their research note that they expect to see ABCL reach a price target of $6. The rating they have provided for ABCL stocks is “Overweight” according to the report published on December 05th, 2023.
ABCL Trading at -8.91% from the 50-Day Moving Average
After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.81% of loss for the given period.
Volatility was left at 5.68%, however, over the last 30 days, the volatility rate increased by 6.41%, as shares sank -14.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.38% lower at present.
During the last 5 trading sessions, ABCL rose by +6.88%, which changed the moving average for the period of 200-days by -48.54% in comparison to the 20-day moving average, which settled at $3.99. In addition, AbCellera Biologics Inc saw -29.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABCL starting from Thermopylae Holdings Ltd., who purchase 153,000 shares at the price of $6.52 back on May 26 ’23. After this action, Thermopylae Holdings Ltd. now owns 56,012,493 shares of AbCellera Biologics Inc, valued at $997,728 using the latest closing price.
Booth Andrew, the Chief Financial Officer of AbCellera Biologics Inc, purchase 14,500 shares at $6.85 during a trade that took place back on May 26 ’23, which means that Booth Andrew is holding 153,000 shares at $99,325 based on the most recent closing price.
Stock Fundamentals for ABCL
Current profitability levels for the company are sitting at:
- -6.15 for the present operating margin
- -1.01 for the gross margin
The net margin for AbCellera Biologics Inc stands at -3.85. The total capital return value is set at -0.17. Equity return is now at value -12.27, with -9.67 for asset returns.
Based on AbCellera Biologics Inc (ABCL), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -0.57. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 13.98.
Currently, EBITDA for the company is -192.16 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 29.63. The receivables turnover for the company is 0.59for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
In summary, AbCellera Biologics Inc (ABCL) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
